Role of Vitamin D Supplementation in Treatment of BPPV Patients

Abstract

Aim: The aim of the study is to study the outcomes of Vitamin D supplements along with Betahistine as compared to Betahistine alone in the treatment of benign paroxysmal positional vertigo (BPPV) patients. Background: BPPV is the most prevalent neuro-otological circumstance which is characterized by episodes of vertigo. Methodology: The research was performed in a tertiary care center in the department of otorhinolaryngology and head-and-neck operation at tertiary care center, India. This was a randomized controlled trial research with records of 50 cases in the year 2021–2022. The average age of the subjects was ± 18 years. A total of 50 cases were classified into two groups, each including 25 patients (Group A: 25 and Group B: 25). Group A received 60,000 IU cholecalciferol weekly along with betahistine for 3 months, whereas Group B received only betahistine. The Institute Ethics Committee (Human Studies) examined and accepted the study protocol (Approval No. JIP/IEC/SC/2016/26/861; Annexure 3). Results: A total of 50 subjects reporting to the otolaryngology clinic with complaints of frequent attacks of dizziness were evaluated for vertigo using a dizziness history questionnaire that promotes greater accountability and flexibility and which is also a well-recognized method among students, physicians who aim to establish a practice in future. After complete preoperative evaluation, the cases were randomly separated into two groups: Group A received 60,000 IU cholecalciferol weekly along with betahistine for 3 months, and Group B received only betahistine. The results of the treatment were compared between two groups. The inter-group continuous variables and intragroup quantitative variables (n = 2) were compared using suitable tools of statistics such as unpaired Student’s t-test. The categorical data were expressed in terms of percentage, rate, and ratio. The association between the result and clinical and demographic characteristics was tested using the Chi-square test or Fisher’s exact test. In the present study, Vitamin D levels were compared between Group A and Group B. Before treatment, Group A had a Vitamin D level of 16.68, whereas Group B had a Vitamin D level of 17.48, whereas Group A showed 19.68 and Group B showed 18.42 posttreatment. In the present investigation, Group A patients showed better outcomes in contrast to Group B patients. Conclusion: This study proves that the addition of Vitamin D along with betahistine in the routine treatment of BPPV reduces the number of recurrent episode of BPPV as well as help with reducing the symptoms of other comorbidities such as migraine and tinnitus.